Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhejiang Univ. RIPK1 compound 21
- Development stage
- Unknown
- Lead developer
- Zhejiang University
01
Overview
Zhejiang Univ. RIPK1 compound 21: sourced facts only. name: "Among them, compound 21 showed obvious improvement in RIPK1 inhibitory activity with an IC50 value of 2.21 μM, accompanied with moderate anti-necroptosis activity in HT-29 cells (IC50 = 15.32 μM)." [PMID:42043293]; target: "Among them, compound 21 showed obvious improvement in RIPK1 inhibitory activity with an IC50 value of 2.21 μM, accompanied with moderate anti-necroptosis activity in HT-29 cells (IC50 = 15.32 μM)." [PMID:42043293]; developer: "College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China." [PMID:42043293]
02
Targets
RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on Zhejiang Univ. RIPK1 compound 21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Univ. RIPK1 compound 21.